(Q27012348)

Journal of Experimental & Clinical Cancer Research

language of work or name

1 reference

1 June 2012

8 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

25 June 2019

29 May 2020

23 September 2020

3 references

25 June 2019

23 September 2020

31

1 reference

page(s)

53

1 reference

Creative Commons Attribution 2.0 Generic

copyright license

7 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

25 June 2019

29 May 2020

on focus list of Wikimedia project

23 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: is it possible?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Lymph node metastasis in grossly apparent clinical stage Ia epithelial ovarian cancer: Hacettepe experience and review of literature.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Is there any possibility of fertility-sparing surgery in patients with clear-cell carcinoma of the ovary?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Treatment options in the management of ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Coordinately up-regulated genes in ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

A pilot study of CPT-11 and cisplatin for ovarian clear cell adenocarcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Pelvic and para-aortic lymphadenectomy in cancer of the ovary

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer

31 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Association of lymphadenectomy and survival in stage I ovarian cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Survival probability in ovarian clear cell adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Phase II study of high-dose megestrol acetate in platinum-refractory epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Surgical and Medical Treatment of Clear Cell Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-9966-31-53

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3405444

Assessment of metastases to aortic and pelvic lymph nodes in epithelial ovarian carcinoma. A proposal for essential sites for lymph node biopsy

28 November 2018

1 reference

12 December 2020

Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience

1 reference

12 December 2020

Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages

1 reference

12 December 2020

Lymphadenectomy in stage I ovarian cancer

1 reference

12 December 2020

Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells

1 reference

12 December 2020

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

1 reference

12 December 2020

Systematic pelvic and paraaortic lymphadenectomy at second-look laparotomy for ovarian cancer

1 reference

12 December 2020

Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer

1 reference

12 December 2020

The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival

1 reference

12 December 2020

Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors

1 reference

12 December 2020

Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary

1 reference

12 December 2020

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis

1 reference

12 December 2020

Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer

1 reference

12 December 2020

Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance

1 reference

12 December 2020

Is there any association between retroperitoneal lymphadenectomy and survival benefit in ovarian clear cell carcinoma patients?

1 reference

12 December 2020

Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial

1 reference

12 December 2020

Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases

1 reference

12 December 2020

Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary

1 reference

12 December 2020

Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0)

1 reference

12 December 2020

Lymph node metastasis in stage I epithelial ovarian cancer

1 reference

12 December 2020

p53 mutation is infrequent in clear cell carcinoma of the ovary

1 reference

12 December 2020

Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas

1 reference

12 December 2020

Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy

1 reference

12 December 2020

Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications

1 reference

12 December 2020

Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer

1 reference

12 December 2020

Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-9966-31-53

1 reference

Dimensions Publication ID

0 references

1 reference

PubMed publication ID

22655678

1 reference